Orthopedic surgery used to feel like the hardware aisle at a discount store. Off-the-shelf parts hammered into human bodies with the hope they’d fit well enough to keep moving. Restor3d looked at that reality and decided it wasn’t just outdated, it was unacceptable. Founded in 2017 out of Duke University by J. Kurt Jacobus, Ph.D., Ken Gall, Ph.D., and Andrew Miller, Ph.D., this Durham-based company bet on a new standard: every patient deserves an implant designed for their anatomy, not for a catalog.
That conviction just earned Restor3d a $104M Series B announced August 22, 2025. Partners Group led with a $65M investment for a significant minority stake, while existing shareholders backed it with another $39M. Stack that on top of their $38M raise in April, $70M Series A in 2024, and $20.1M earlier this year, and the company now sits on more than $232M in total funding. That kind of momentum isn’t noise, it’s signal.
And the signal is clear: Restor3d works. The company already serves over 520 surgeons across 740 hospitals nationwide, with FDA clearances spanning shoulder, hip, knee, ankle, and trauma. Their acquisition of Conformis in 2023 wasn’t just about adding a Boston facility; it was about widening the runway for growth and cementing their leadership in patient-specific orthopedic implants.
The technology turns science fiction into surgical standard. The r3id Personalized Surgery Platform uses AI to transform CT scans into custom implant designs. Laser Powder Bed Fusion prints titanium and cobalt-chrome structures that don’t just replace bone, they integrate with it. Their TIDAL Technology porous architecture invites osseointegration, creating a bond that grows stronger over time. Add polymer printing for instruments and guides, and you’ve got a fully integrated “powder to sterile product” system that redefines speed and precision.
The leadership lineup matches the ambition. J. Kurt Jacobus, Ph.D., brings the CEO playbook from prior medtech exits. Ken Gall, Ph.D., delivers the material science genius that birthed multiple device companies. Andrew Miller, Ph.D., ensures operational rigor. Cambre Kelly, Ph.D., drives AI and design automation with a vision that landed her on Forbes 30 Under 30. Reinforcements like Larry Hazbun, Ph.D., advancing robotics, and Kirstin Widding shaping hip and knee strategy, round out a team ready to scale fast.
The market tailwinds are undeniable. Orthopedic implants represent a $49.4B global market, heading toward $76.4B by 2033. The personalized 3D-printed segment alone is expected to nearly double by 2030. With demographics aging and activity levels climbing, Restor3d is positioned to meet demand that only grows sharper with time.
Partners Group saw the future and bought in. Summers Value Partners, Trinity Capital, and Duke Capital Partners believed early and kept believing. The only question left is how long before personalized implants stop being the alternative and start being the standard.
